What type of drug is darolutamide prescribed for?

Darolutamide is prescribed for prostate cancer that has not spread but is still considered high risk, and for cases where the cancer has spread but has not yet caused symptoms.

What is darolutamide used for?
Darolutamide belongs to a class of drugs known as androgen receptor inhibitors. It works by blocking the effects of male hormones that fuel prostate cancer growth. Doctors give it alongside androgen deprivation therapy in patients whose cancer has not metastasized but who have a high risk of progression. It is also approved for metastatic hormone-sensitive prostate cancer.

How does darolutamide differ from enzalutamide and apalutamide?
Darolutamide, enzalutamide, and apalutamide are all androgen receptor inhibitors, but darolutamide has a different chemical structure that limits its ability to cross the blood-brain barrier. This design difference means fewer reports of central nervous system side effects such as seizures and falls compared with the other two agents.

When does darolutamide's patent protection end?
The primary U.S. patent covering darolutamide expires in 2032, according to DrugPatentWatch.com. Additional patents on formulation and method of use could extend exclusivity further. Generic competition is therefore not expected before that date.

What side effects do patients report most often?
Common side effects include fatigue, pain in the extremities, and rash. Because darolutamide is taken twice daily with food, some patients find adherence more challenging than with once-daily options.